

John Carl Panetta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7807411/publications.pdf>

Version: 2024-02-01

157
papers

7,425
citations

47006

47
h-index

60623

81
g-index

161
all docs

161
docs citations

161
times ranked

8459
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. <i>Haematologica</i> , 2022, 107, 371-380.	3.5	5
2	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. <i>Blood Advances</i> , 2022, 6, 2824-2834.	5.2	3
3	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and <i>FLT3</i> -Internal Tandem Duplication. <i>Clinical Cancer Research</i> , 2022, 28, 2536-2546.	7.0	3
4	Combining SJ733, an oral ATP4 inhibitor of <i>Plasmodium falciparum</i> , with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. <i>EBioMedicine</i> , 2022, 80, 104065.	6.1	4
5	Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 3316.	2.4	6
6	The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics. <i>Molecular Cancer Research</i> , 2021, 19, 636-650.	3.4	8
7	Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. <i>Cancer</i> , 2021, 127, 2074-2082.	4.1	2
8	Limited sampling strategies for accurate determination of extended half-life factor VIII pharmacokinetics in severe haemophilia A patients. <i>Haemophilia</i> , 2021, 27, 408-416.	2.1	5
9	Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy. <i>Cancer</i> , 2021, 127, 3202-3213.	4.1	4
10	Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. <i>Clinical and Translational Science</i> , 2021, 14, 1490-1504.	3.1	12
11	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 655-664.	2.3	5
12	Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study. <i>Clinical and Translational Science</i> , 2021, 14, 2152-2160.	3.1	2
13	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 130-135.e1.	0.4	2
14	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28040.	1.5	38
15	Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 362-371.	2.4	17
16	Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. <i>Blood</i> , 2020, 136, 2955-2958.	1.4	3
17	Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 711-717.	2.3	6
18	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	4.1	12

#	ARTICLE	IF	CITATIONS
19	Predicting success of desensitization after pegaspargase allergy. <i>Blood</i> , 2020, 135, 71-75.	1.4	20
20	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 329-344.	13.2	44
21	Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e177-e181.	2.5	9
22	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. <i>Cancers</i> , 2020, 12, 1789.	3.7	18
23	Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28244.	1.5	5
24	Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 964-975.	9.1	47
25	Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo. <i>Journal of Clinical Investigation</i> , 2020, 130, 6600-6615.	8.2	18
26	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 7320-7330.	7.0	14
27	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. <i>Journal of Clinical Oncology</i> , 2019, 37, 2051-2061.	1.6	61
28	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. <i>PLoS ONE</i> , 2019, 14, e0216328.	2.5	7
29	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S196.	2.0	1
30	Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassemia Major Undergoing HSCT. <i>Blood</i> , 2019, 134, 1977-1977.	1.4	0
31	Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1014-1022.	3.3	23
32	Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 575-583.	4.7	22
33	Bone mineral density in children with acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 1025-1035.	4.1	21
34	Genetic Variants in Drug Metabolizing and Transporter Genes Explain Variability in Fludarabine Pharmacokinetics in Patients Undergoing HSCT. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S80.	2.0	1
35	Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 4248-4259.	4.1	43
36	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. <i>Blood</i> , 2018, 132, 2697-2697.	1.4	2

#	ARTICLE	IF	CITATIONS
37	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 2665-2665.	1.4	0
38	Genome-Wide Study Links <i>PNPLA3</i> Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 131-140.	4.7	50
39	The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2017, 7, e531-e531.	6.2	25
40	Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 977-983.	2.4	5
41	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 294-302.	1.5	17
42	Pharmacokinetics of a Generic Treosulfan in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S301-S302.	2.0	1
43	Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 7558-7568.	7.0	23
44	Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 449-452.	0.6	17
45	Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1039-1052.	2.3	38
46	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1116-1122.	3.3	15
47	Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1051-1058.	2.3	20
48	Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1217-1223.	2.3	20
49	Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. <i>Blood</i> , 2016, 128, 3937-3937.	1.4	3
50	A 5'UTR Polymorphism in NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen. <i>Blood</i> , 2016, 128, 984-984.	1.4	2
51	MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. <i>PLoS Computational Biology</i> , 2016, 12, e1004744.	3.2	62
52	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 179-179.	1.4	0
53	Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death. <i>Scientific Reports</i> , 2015, 5, 16488.	3.3	8
54	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. <i>Cancer Research</i> , 2015, 75, 2729-2736.	0.9	59

#	ARTICLE	IF	CITATIONS
55	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. <i>Nature Genetics</i> , 2015, 47, 607-614.	21.4	126
56	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 343-356.	16.8	145
57	Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 27-35.	2.3	25
58	Population Pharmacokinetics of Fludarabine and Treosulfan in Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3120-3120.	1.4	6
59	Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. <i>Blood</i> , 2015, 126, 3695-3695.	1.4	6
60	Abstract 4526: Age dependent disposition of cyclophosphamide (CTX) and metabolites in infants \geq 1 year old with brain tumors. , 2015, , .		0
61	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1299-1299.	1.4	0
62	Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring. <i>Blood</i> , 2015, 126, 4322-4322.	1.4	1
63	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 949-959.	1.6	275
64	Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 373-375.	1.5	11
65	Voriconazole plasma concentrations in immunocompromised pediatric patients vary by <i>CYP2C19</i> diplotypes. <i>Pharmacogenomics</i> , 2014, 15, 1065-1078.	1.3	59
66	Successful challenges using native <i>E. coli</i> asparaginase after hypersensitivity reactions to PEGylated <i>E. coli</i> asparaginase. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1307-1313.	2.3	20
67	Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1224-1228.	2.0	10
68	Abstract CT409: Dexamethasone (dex) and asparaginase increase triglycerides during acute lymphoblastic leukemia (ALL) therapy in children. , 2014, , .		0
69	Population Pharmacokinetics of Daunorubicin in AML: Influence on Clinical Outcome. <i>Blood</i> , 2014, 124, 902-902.	1.4	0
70	Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 3884-3884.	1.4	0
71	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 369-378.	2.3	36
72	Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 236-246.	7.0	64

#	ARTICLE	IF	CITATIONS
73	Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2013, 19, 3050-3058.	7.0	82
74	Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow. <i>Cancer Research</i> , 2013, 73, 6111-6117.	0.9	19
75	Mathematical modeling of folate metabolism. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2013, 5, 603-613.	6.6	6
76	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013, 121, 898-904.	1.4	174
77	Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 1178-1185.	2.4	15
78	Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 1658-1664.	1.4	77
79	Phase I Study of the Tolerability and Pharmacokinetics of Palifermin in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1309-1314.	2.0	21
80	Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. <i>Leukemia</i> , 2012, 26, 2303-2309.	7.2	93
81	Population PK/PD Model of Homocysteine Concentrations after High-Dose Methotrexate Treatment in Patients with Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2012, 7, e46015.	2.5	27
82	Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. <i>Cancer</i> , 2012, 118, 4321-4330.	4.1	62
83	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1. <i>Blood</i> , 2012, 120, 2466-2466.	1.4	5
84	Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1771-1778.	1.6	45
85	Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration. <i>Drug Metabolism and Disposition</i> , 2011, 39, 15-21.	3.3	53
86	Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2011, 117, 2340-2347.	1.4	219
87	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. <i>Journal of the National Cancer Institute</i> , 2011, 103, 893-905.	6.3	50
88	Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β^2 -Thalassemia Major Undergoing Allogeneic HSCT. <i>Blood</i> , 2011, 118, 1941-1941.	1.4	1
89	Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 2550-2550.	1.4	0
90	Clinical Utility and Implications of Asparaginase Antibodies in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 1481-1481.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma. <i>Clinical Cancer Research</i> , 2010, 16, 1049-1057.	7.0	11
92	Genetic Predictors of Interindividual Variability in Hepatic CYP3A4 Expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 1088-1099.	2.5	98
93	Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells. <i>PLoS Computational Biology</i> , 2010, 6, e1001019.	3.2	46
94	Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. <i>European Journal of Cancer</i> , 2010, 46, 1848-1855.	2.8	39
95	Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Determinants of Osteonecrosis In Children with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2010, 116, 1033-1033.	1.4	1
96	P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice. <i>Drug Metabolism Letters</i> , 2010, 4, 195-201.	0.8	29
97	Abstract 2758: Population pharmacokinetics of cyclophosphamide in infants and young children. , 2010, , .		0
98	Compartment-Specific Roles of ATP-Binding Cassette Transporters Define Differential Topotecan Distribution in Brain Parenchyma and Cerebrospinal Fluid. <i>Cancer Research</i> , 2009, 69, 5885-5892.	0.9	52
99	Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 4599-4604.	1.6	53
100	Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects. <i>Journal of Clinical Oncology</i> , 2009, 27, 5972-5978.	1.6	305
101	Pharmacokinetics of Erlotinib for the Treatment of High-Grade Glioma in a Pediatric Patient with Cystic Fibrosis: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2009, 29, 858-866.	2.6	13
102	Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. <i>Biomedical Chromatography</i> , 2009, 23, 707-713.	1.7	15
103	Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 651-658.	4.7	66
104	Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 274-278.	2.0	47
105	Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation.. <i>Blood</i> , 2009, 114, 1182-1182.	1.4	2
106	Population Pharmacokinetics of Busulfan in Patients with Beta Thalassemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation.. <i>Blood</i> , 2009, 114, 3349-3349.	1.4	0
107	Pharmacogenetic Pathway Analysis of Irinotecan. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 393-402.	4.7	41
108	The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1792-1803.	6.3	61

#	ARTICLE	IF	CITATIONS
109	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. <i>PLoS Medicine</i> , 2008, 5, e83.	8.4	75
110	Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma. <i>Clinical Cancer Research</i> , 2008, 14, 318-325.	7.0	55
111	Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 1932-1939.	1.6	129
112	A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of Methotrexate Pharmacokinetics and Adverse Effects. <i>Blood</i> , 2008, 112, 214-214.	1.4	8
113	Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients. <i>Clinical Cancer Research</i> , 2007, 13, 6703-6711.	7.0	21
114	Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter snp that alters PARP1 binding and SMARCB1 expression. <i>Human Molecular Genetics</i> , 2007, 16, 2261-2271.	2.9	38
115	Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420. <i>Clinical Cancer Research</i> , 2007, 13, 1511-1515.	7.0	89
116	UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan. <i>Journal of Clinical Oncology</i> , 2007, 25, 2594-2600.	1.6	84
117	Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. <i>Blood</i> , 2006, 108, 3997-4002.	1.4	89
118	Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 15-24.	2.3	22
119	Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 475-482.	2.3	11
120	Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor. <i>Cancer Research</i> , 2006, 66, 11305-11313.	0.9	79
121	Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. <i>Neuro-Oncology</i> , 2006, 8, 89-95.	1.2	11
122	Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 563-570.	1.6	70
123	Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters <i>in vivo</i> . <i>Cancer Research</i> , 2006, 66, 4802-4807.	0.9	154
124	Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells. <i>British Journal of Cancer</i> , 2006, 94, 93-100.	6.4	35
125	Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after <i>in vivo</i> mercaptopurine treatment. <i>Blood</i> , 2005, 106, 1778-1785.	1.4	53
126	Population pharmacokinetic studies in pediatrics: Issues in design and analysis. <i>AAPS Journal</i> , 2005, 7, E475-E487.	4.4	163

#	ARTICLE	IF	CITATIONS
127	Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 433-438.	2.3	8
128	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. <i>Journal of Clinical Investigation</i> , 2005, 115, 110-117.	8.2	129
129	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. <i>Journal of Clinical Investigation</i> , 2005, 115, 477-477.	8.2	0
130	Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy. <i>Molecular and Cellular Biology</i> , 2004, 24, 7612-7621.	2.3	403
131	Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice. <i>Cancer Research</i> , 2004, 64, 7491-7499.	0.9	193
132	Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 829-837.	1.6	29
133	Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 253-260.	2.3	17
134	Late-onset delayed excretion of methotrexate. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 146-52.	2.3	30
135	High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. <i>Cancer</i> , 2004, 100, 1724-1733.	4.1	118
136	Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 435-441.	2.3	48
137	A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. <i>Mathematical Biosciences</i> , 2003, 186, 29-41.	1.9	37
138	Optimal Control Applied to Competing Chemotherapeutic Cell-Kill Strategies. <i>SIAM Journal on Applied Mathematics</i> , 2003, 63, 1954-1971.	1.8	96
139	Msh2 Deficiency Attenuates But Does Not Abolish Thiopurine Hematopoietic Toxicity in Msh2 ^{-/-} Mice. <i>Molecular Pharmacology</i> , 2003, 64, 456-465.	2.3	11
140	Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 1340-1346.	1.6	34
141	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 419-428.	2.3	43
142	Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2002, 29, 171-188.	1.8	21
143	Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. <i>Clinical Cancer Research</i> , 2002, 8, 2423-9.	7.0	38
144	A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. <i>Mathematical Biosciences</i> , 2001, 170, 1-16.	1.9	35

#	ARTICLE	IF	CITATIONS
145	Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB Journal, 2001, 15, 1902-1908.	0.5	13
146	Modelling the Effects of Paclitaxel and Cisplatin on Breast and Ovarian Cancer. Journal of Theoretical Medicine, 2000, 3, 11-23.	0.5	2
147	Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy. SIAM Journal on Applied Mathematics, 2000, 60, 1059-1072.	1.8	130
148	Molecular biology of breast metastasis The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Research, 2000, 2, 430-5.	5.0	64
149	Modeling immunotherapy of the tumor - immune interaction. Journal of Mathematical Biology, 1998, 37, 235-252.	1.9	699
150	A mathematical model of drug resistance: Heterogeneous tumors. Mathematical Biosciences, 1998, 147, 41-61.	1.9	90
151	A mathematical model of breast and ovarian cancer treated with paclitaxel. Mathematical Biosciences, 1997, 146, 89-113.	1.9	77
152	A logistic model of periodic chemotherapy with drug resistance. Applied Mathematics Letters, 1997, 10, 123-127.	2.7	17
153	A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment. Bulletin of Mathematical Biology, 1996, 58, 425-447.	1.9	197
154	A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment. Bulletin of Mathematical Biology, 1996, 58, 425-447.	1.9	15
155	A logistic model of periodic chemotherapy. Applied Mathematics Letters, 1995, 8, 83-86.	2.7	30
156	A mathematical model of cycle-specific chemotherapy. Mathematical and Computer Modelling, 1995, 22, 67-82.	2.0	115
157	A simple mathematical model and alternative paradigm for certain chemotherapeutic regimens. Mathematical and Computer Modelling, 1995, 22, 49-60.	2.0	26